瑞替普酶及尿激酶静脉溶栓治疗急性心肌梗死的疗效体会

Curative Effect Experience of Intravenous Thrombolysis with Reteplase and Urokinase on Acute Myocardial Infarction

目的研究瑞替普酶及尿激酶静脉溶栓治疗急性心肌梗死的疗效。方法取2016年10月至2018年11月我院急性心肌梗死患者92例作为研究对象,随机分研究组(瑞替普酶)与对照组(尿激酶)各46例,评估两组血清炎性因子水平、冠脉再通成功率与不良反应发生率。结果研究组血清炎性因子较对照组改善优异,研究组冠状动脉再通成功率较对照组高,不良反应发生率低,P<0.05(具统计学差异)。结论由此可证:与尿激酶相比,对急性心肌梗死患者采用瑞替普酶静脉溶栓治疗能显著提高冠状动脉再通成功率,改善血清炎性因子水平,避免患者发生牙龈出血或消化道出血等不良反应,安全性高,值得借鉴。

Objective To study curative effect of intravenous thrombolysis combined with reteplase and urokinase on acute myocardial infarction.Methods Choose 92 cases acute myocardial infarction patients in our hospital from October 2016 to November 2018 as study objects.Divide them into research group(reteplase)and control group(urokinase)randomly,46 cases in each group.Evaluate levels of serum inflammatory factors,successful rate of coronary artery recanalization and incidence of adverse reactions were.Results Improvement of serum inflammatory factors in research group was better than control group.Success rate of coronary artery recanalization in research group was higher than control group,and adverse reactions incidence was lower(P<0.05,with statistical difference).Conclusion It can be confirmed,compared with urokinase,intravenous thrombolytic therapy with reteplase can improve success rate of coronary artery recanalization significantly of acute myocardial infarction patients,improve level of serum inflammatory factors,and avoid adverse reactions such as gingival bleeding or gastrointestinal bleeding,which is safe and worthy of reference.